Mineralys Therapeutics Inc
MLYS45.630USD
+1.130+2.54%
交易中 （美东）报价延迟15分钟
3.00B总市值
亏损市盈率 TTM
关于 Mineralys Therapeutics Inc 公司
Mineralys Therapeutics, Inc. 是一家临床阶段的生物制药公司。该公司专注于开发针对高血压、慢性肾病 (CKD) 和其他由醛固酮异常升高引起的疾病的药物。该公司的候选产品 lorundrostat 是一种专有的口服高选择性醛固酮合酶抑制剂 (ASI)，该公司最初正在开发用于治疗不受控制的高血压 (uHTN) 患者。Lorundrostat 旨在通过抑制负责产生激素的酶 CYP11B2 来降低醛固酮水平。该公司完成了 Target-HTN 试验，这是一项针对 lorundrostat 治疗 uHTN 的 II 期概念验证试验。除了高血压之外，该公司还打算开发用于治疗慢性肾病 (CKD) 的 lorundrostat。
Mineralys Therapeutics Inc简介
公司代码MLYS
公司名称Mineralys Therapeutics Inc
上市日期Feb 10, 2023
CEOMr. Jon Congleton
员工数量51
证券类型Ordinary Share
年结日Feb 10
公司地址150 N. Radnor Chester Road
城市RADNOR
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编19087
电话18883786240
网址https://mineralystx.com/
公司代码MLYS
上市日期Feb 10, 2023
CEOMr. Jon Congleton
Mineralys Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Jon Congleton
Mr. Jon Congleton
Chief Executive Officer, Director
Chief Executive Officer, Director
663.52K
-2.23%
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
588.24K
--
Mr. Adam Scott Levy
Mr. Adam Scott Levy
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
51.95K
-17.16%
Mr. Glenn P. Sblendorio
Mr. Glenn P. Sblendorio
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Alexander M. Gold, M.D.
Mr. Alexander M. Gold, M.D.
Independent Director
Independent Director
--
--
Dr. David M. Rodman, M.D.
Dr. David M. Rodman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Daphne Karydas
Ms. Daphne Karydas
Independent Director
Independent Director
--
--
Dr. Brian Taylor (Bt) Slingsby, M.D., Ph.D.
Dr. Brian Taylor (Bt) Slingsby, M.D., Ph.D.
Founder, Independent Director
Founder, Independent Director
--
--
Dr. Derek DiRocco, Ph.D.
Dr. Derek DiRocco, Ph.D.
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Jon Congleton
Mr. Jon Congleton
Chief Executive Officer, Director
Chief Executive Officer, Director
663.52K
-2.23%
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
588.24K
--
Mr. Adam Scott Levy
Mr. Adam Scott Levy
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
51.95K
-17.16%
Mr. Glenn P. Sblendorio
Mr. Glenn P. Sblendorio
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Alexander M. Gold, M.D.
Mr. Alexander M. Gold, M.D.
Independent Director
Independent Director
--
--
Dr. David M. Rodman, M.D.
Dr. David M. Rodman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 11月7日 周五
更新时间: 11月7日 周五
持股股东
股东类型
持股股东
持股股东
占比
Catalys Pacific, LLC
11.79%
RA Capital Management, LP
9.70%
Samsara BioCapital, LLC
7.51%
SR One Capital Management, LP
4.14%
The Vanguard Group, Inc.
3.98%
其他
62.88%
持股股东
持股股东
占比
Catalys Pacific, LLC
11.79%
RA Capital Management, LP
9.70%
Samsara BioCapital, LLC
7.51%
SR One Capital Management, LP
4.14%
The Vanguard Group, Inc.
3.98%
其他
62.88%
股东类型
持股股东
占比
Venture Capital
33.14%
Investment Advisor
26.65%
Hedge Fund
19.68%
Investment Advisor/Hedge Fund
14.86%
Private Equity
5.26%
Individual Investor
1.82%
Research Firm
1.60%
Bank and Trust
0.16%
Pension Fund
0.13%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
315
76.75M
101.61%
+1.04M
2025Q2
287
68.74M
105.48%
+8.03M
2025Q1
278
68.91M
105.92%
+7.50M
2024Q4
230
53.93M
108.22%
-5.12M
2024Q3
214
51.53M
103.61%
-6.38M
2024Q2
197
51.29M
104.21%
-4.08M
2024Q1
188
49.20M
100.04%
-4.93M
2023Q4
172
42.00M
101.88%
-1.03M
2023Q3
140
43.25M
105.60%
+16.34M
2023Q2
116
41.91M
102.57%
+17.25M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Catalys Pacific, LLC
8.90M
11.79%
--
--
Jun 30, 2025
RA Capital Management, LP
7.32M
9.7%
+1.18M
+19.14%
Sep 04, 2025
Samsara BioCapital, LLC
5.67M
7.51%
--
--
Sep 04, 2025
SR One Capital Management, LP
3.13M
4.14%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
2.32M
3.07%
+283.58K
+13.93%
Jun 30, 2025
Capital International Investors
2.90M
3.84%
+2.90M
--
Jun 30, 2025
Andera Partners S.A.S.
2.77M
3.66%
-100.00K
-3.49%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.74M
3.62%
+532.75K
+24.18%
Jun 30, 2025
Integral Health Asset Management, LLC
2.70M
3.57%
+400.00K
+17.39%
Jun 30, 2025
Capital World Investors
2.90M
3.84%
+2.90M
--
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
Simplify Health Care ETF
6.55%
Invesco Dorsey Wright Healthcare Momentum ETF
2.36%
Virtus LifeSci Biotech Clinical Trials ETF
1.83%
Invesco Dorsey Wright SmallCap Momentum ETF
0.54%
SPDR S&P Biotech ETF
0.31%
iShares Micro-Cap ETF
0.28%
ProShares Ultra Nasdaq Biotechnology
0.26%
Invesco Nasdaq Biotechnology ETF
0.25%
Optimize Strategy Index ETF
0.24%
Vanguard US Momentum Factor ETF
0.19%
查看更多
Simplify Health Care ETF
占比6.55%
Invesco Dorsey Wright Healthcare Momentum ETF
占比2.36%
Virtus LifeSci Biotech Clinical Trials ETF
占比1.83%
Invesco Dorsey Wright SmallCap Momentum ETF
占比0.54%
SPDR S&P Biotech ETF
占比0.31%
iShares Micro-Cap ETF
占比0.28%
ProShares Ultra Nasdaq Biotechnology
占比0.26%
Invesco Nasdaq Biotechnology ETF
占比0.25%
Optimize Strategy Index ETF
占比0.24%
Vanguard US Momentum Factor ETF
占比0.19%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
